Related references
Note: Only part of the references are listed.A Big Bang model of human colorectal tumor growth
Andrea Sottoriva et al.
NATURE GENETICS (2015)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2014)
Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications
Vivian Kosmidou et al.
HUMAN MUTATION (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
A. Rose Brannon et al.
GENOME BIOLOGY (2014)
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
D. Tougeron et al.
ANNALS OF ONCOLOGY (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
Antonella De Luca et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
Evolution of intratumoral genetic heterogeneity during colorectal cancer progression
L Losi et al.
CARCINOGENESIS (2005)
Share Paper
